Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by University Health Network, Toronto
Information provided by (Responsible Party):
University Health Network, Toronto Identifier:
First received: January 17, 2011
Last updated: June 24, 2014
Last verified: June 2014

January 17, 2011
June 24, 2014
November 2010
November 2015   (final data collection date for primary outcome measure)
To determine the pattern of practice for management (immediate radiotherapy, deferred radiotherapy) of patients with ACLA-NSCLC, including reasons, timing and dose fractionation of lung/mediastinal RT [ Time Frame: 6 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01279408 on Archive Site
  • To describe the patient reported outcomes (symptoms, toxicities and quality of life measures) in patients with ACLA-NSCLC at 4 and 12 months [ Time Frame: 6 years ] [ Designated as safety issue: No ]
  • To explore the relationship between utility and initial treatment decision (immediate versus deferred) [ Time Frame: 6 years ] [ Designated as safety issue: No ]
  • To describe the disease status (as per CT imaging) at 4 months [ Time Frame: 6 years ] [ Designated as safety issue: No ]
  • To describe the overall survival in patients with ACLA-NSCLC [ Time Frame: 6 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)
Prospective Observational Study Of Patients With Asymptomatic Centrally Located Advanced NSCLC Who Are Not Suitable For Curative Treatment

The aim of the study is to assess current practice within PROP & lung teams, for treating asymptomatic patients with centrally located non-small cell lung cancer (NSCLC), and to observe outcomes for those patients receiving immediate or deferred RT. This is a prospective cohort trial. Patients will be managed by immediate radiotherapy (RT) or a deferred approach according to physicians' individual current clinical practice. Baseline and follow-up data collection will be structured to focus on patient-reported measures to describe clinical outcomes in the two management groups. Indications for prescribing RT and dose fractionation schedules will also be collected. A new intervention will not be introduced during this trial. Instead, a follow-up regimen will be offered to both groups of patients, so that RT can be offered to the deferred group of patients if/when symptoms develop, and we can monitor symptoms/toxicities and QoL in both groups of patients.

Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Patients with Centrally Located Advanced NSCLC who are Asymptomatic and who are not Suitable for Curative Treatment

Non-small Cell Lung Carcinoma
Other: None: Questionnaire Study
Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2015
November 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed NSCLC
  • Central disease, as defined by tumour (either primary or nodal disease) arising or extending within a 2cm circumferential expansion from the centre of the trachea or within the zone of the proximal bronchial tree
  • Disease is visible on thoracic CT (diagnostic or simulation)
  • Asymptomatic from intra-thoracic tumour (may have background chest symptoms related to underlying COAD etc, but these symptoms must not have worsened due to tumour)
  • Patient (due to age or co-morbidities) or tumour (due to locally advanced or metastatic disease) is not suitable for radical treatment (defined as surgery or RT dose >50Gy in 20 fractions or equivalent).
  • Previous chemotherapy, thoracic RT or surgery is allowed
  • RT to other metastases (e.g. brain, bone etc) is allowed

    •≥ 18 years of age

  • Able to provide written informed consent

Exclusion Criteria:

  • Intra-thoracic disease is peripheral only, not extending within 2cm of trachea/proximal bronchial tree
  • Symptomatic from intra-thoracic NSCLC
  • Histological diagnosis of small cell lung cancer, or malignant mediastinal lymphadenopathy from another malignancy (not NSCLC)
18 Years and older
Contact: Rebecca Wong, MBChB 416 946 4501 ext 2126
UHN REB 10-0484-CE
University Health Network, Toronto
University Health Network, Toronto
Not Provided
Principal Investigator: Rebecca Wong, MBChB University Health Network, Princess Margaret Hospital
University Health Network, Toronto
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP